{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:12:31Z","timestamp":1780456351884,"version":"3.54.1"},"reference-count":49,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Epithelial-to-mesenchymal transition (EMT) is a critical process in malignant ovarian cancer metastasis. EMT involves the conversion of epithelial cells to mesenchymal cells, conferring enhanced migratory and invasive capabilities. Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor and exhibits an aggressive invasive phenotype that mimics some steps of EMT but does not undergo true metastasis, i.e., the invasion of other organ systems. This study conducts a comparative genomic analysis of EMT in ovarian cancer and invasion in GBM\u2014two malignancies characterized by poor prognosis and limited therapies. Investigating the molecular biology in ovarian cancer and GBM demonstrates shared mechanisms of tumor progression, such as similar genetic and molecular pathways influencing cell plasticity, invasion, and resistance to therapy. The comparative analysis reveals commonalities and differences in the regulatory networks and gene expression profiles associated with EMT and invasion in these cancers. Key findings include the identification of core EMT regulators, such as TWIST1, SNAIL, and ZEB1, which are upregulated in both ovarian cancer and GBM, promoting mesenchymal phenotypes and metastasis. Additionally, the analysis uncovers EMT-related pathways, such as the PI3K\/AKT and TGF-\u03b2 signaling, which are critical in both cancers but exhibit distinct regulatory dynamics. Understanding the intricacies of EMT in ovarian cancer and invasion in GBM provides valuable insights into their aggressive behavior and identifies potential common therapeutic targets. The findings stress the importance of targeting EMT\/invasion transitions to develop effective treatments to halt progression and improve patient outcomes in these malignancies.<\/jats:p>","DOI":"10.3390\/cells14030171","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T09:01:13Z","timestamp":1737622873000},"page":"171","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Similarities in Mechanisms of Ovarian Cancer Metastasis and Brain Glioblastoma Multiforme Invasion Suggest Common Therapeutic Targets"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4471-486X","authenticated-orcid":false,"given":"Gia A.","family":"Jackson","sequence":"first","affiliation":[{"name":"Neurosurgery Section, Atlanta VA Healthcare System, School of Medicine, Mercer University, Georgia Neurosurgical Institute, Macon, GA 31207, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Cory","family":"Adamson","sequence":"additional","affiliation":[{"name":"Neurosurgery Section, Atlanta VA Healthcare System, School of Medicine, Mercer University, Georgia Neurosurgical Institute, Macon, GA 31207, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41568-022-00503-z","article-title":"Immunobiology of high-grade serous ovarian cancer: Lessons for clinical translation","volume":"22","author":"Kandalaft","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Tavares, V., Marques, I.S., Melo, I.G., Assis, J., Pereira, D., and Medeiros, R. (2024). Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031845"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/jmri.28743","article-title":"The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 1-Key Points of the Fifth Edition and Summary of Imaging Findings on Adult-Type Diffuse Gliomas","volume":"58","author":"Park","year":"2023","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_4","unstructured":"Kanderi, T., Munakomi, S., and Gupta, V. (2024). Glioblastoma Multiforme. StatPearls, StatPearls Publishing."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Fisher, J.P., and Adamson, D.C. (2021). Current FDA-Approved Therapies for High-Grade Malignant Gliomas. Biomedicines, 9.","DOI":"10.3390\/biomedicines9030324"},{"key":"ref_6","unstructured":"Jackson, G. (2024, November 26). Figure Created Using BioRender. Available online: https:\/\/BioRender.com\/q44d591."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.tcb.2020.07.003","article-title":"EMT, MET, Plasticity, and Tumor Metastasis","volume":"30","author":"Bakir","year":"2020","journal-title":"Trends Cell Biol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Debnath, P., Huirem, R.S., Dutta, P., and Palchaudhuri, S. (2022). Epithelial-mesenchymal transition and its transcription factors. Biosci. Rep., 42.","DOI":"10.1042\/BSR20211754"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ribatti, D., Tamma, R., and Annese, T. (2020). Epithelial-Mesenchymal Transition in Cancer: A Historical Overview. Transl. Oncol., 13.","DOI":"10.1016\/j.tranon.2020.100773"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","article-title":"The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis","volume":"15","author":"Huang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_11","unstructured":"Jackson, G. (2024, November 26). Figure created using BioRender. Available online: https:\/\/BioRender.com\/u82q109."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.5487\/TR.2010.26.4.245","article-title":"Epithelial-mesenchymal Transition and Cell Invasion","volume":"26","author":"Son","year":"2010","journal-title":"Toxicol. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"11149","DOI":"10.1002\/cam4.5698","article-title":"Role of tumor microenvironment in cancer progression and therapeutic strategy","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med."},{"key":"ref_14","unstructured":"Arora, T., Mullangi, S., Vadakekut, E.S., and Lekkala, M.R. (2024). Epithelial Ovarian Cancer. StatPearls, StatPearls Publishing."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Azzalini, E., Stanta, G., Canzonieri, V., and Bonin, S. (2023). Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242015077"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.molonc.2009.02.001","article-title":"The contribution of BRCA1 and BRCA2 to ovarian cancer","volume":"3","author":"Ramus","year":"2009","journal-title":"Mol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.7150\/jca.15556","article-title":"Genomic\/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice","volume":"7","author":"Dong","year":"2016","journal-title":"J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"650","DOI":"10.21037\/tcr.2016.08.40","article-title":"TP53 mutations in epithelial ovarian cancer","volume":"5","author":"Zhang","year":"2016","journal-title":"Transl. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s40265-023-01934-0","article-title":"Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options","volume":"83","author":"Garg","year":"2023","journal-title":"Drugs"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5732\/cjc.014.10289","article-title":"The PI3K\/Akt\/mTOR pathway in ovarian cancer: Therapeutic opportunities and challenges","volume":"34","author":"Cheaib","year":"2015","journal-title":"Chin. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12943-016-0502-x","article-title":"Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications","volume":"15","author":"Maziveyi","year":"2016","journal-title":"Mol. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Wu, W., Klockow, J.L., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., and Daldrup-Link, H.E. (2021). Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacol. Res., 171.","DOI":"10.1016\/j.phrs.2021.105780"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3892\/ijo.2021.5194","article-title":"Interleukin-8 released by cancer-associated fibroblasts attenuates the autophagy and promotes the migration of ovarian cancer cells","volume":"58","author":"Thongchot","year":"2021","journal-title":"Int. J. Oncol."},{"key":"ref_24","unstructured":"Jackson, G. (2024, November 26). Figure Created Using BioRender. Available online: https:\/\/BioRender.com\/u02w473."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.apsb.2020.04.004","article-title":"The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy","volume":"10","author":"Yang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Yang, Y., Yang, Y., Yang, J., Zhao, X., and Wei, X. (2020). Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.00758"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"24041","DOI":"10.18632\/oncotarget.25275","article-title":"Pericytes\/vessel-associated mural cells (VAMCs) are the major source of key epithelial-mesenchymal transition (EMT) factors SLUG and TWIST in human glioma","volume":"9","author":"Blank","year":"2018","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-12-3002","article-title":"The definition of primary and secondary glioblastoma","volume":"19","author":"Ohgaki","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"De Vleeschouwer, S. (2017). Epidemiology and Outcome of Glioblastoma. Glioblastoma, Codon Publications.","DOI":"10.15586\/codon.glioblastoma.2017"},{"key":"ref_30","unstructured":"Jackson, G. (2024, November 26). Figure Created Using BioRender. Available online: https:\/\/BioRender.com\/e29e095."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., and Saoud, K. (2018). The p53 Pathway in Glioblastoma. Cancers, 10.","DOI":"10.3390\/cancers10090297"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: Signaling pathways and targeted therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11910-013-0345-4","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"13","author":"Cohen","year":"2013","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/neuonc\/noab203","article-title":"Telomerase as a therapeutic target in glioblastoma","volume":"23","author":"Aquilanti","year":"2021","journal-title":"Neuro Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/cns.12232","article-title":"AJAP1 is dysregulated at an early stage of gliomagenesis and suppresses invasion through cytoskeleton reorganization","volume":"20","author":"Han","year":"2014","journal-title":"CNS Neurosci. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.canlet.2017.06.007","article-title":"EGFR\/EGFRvIII remodels the cytoskeleton via epigenetic silencing of AJAP1 in glioma cells","volume":"403","author":"Yang","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2147\/CMAR.S186142","article-title":"The unique invasiveness of glioblastoma and possible drug targets on extracellular matrix","volume":"11","author":"Hatoum","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Sharma, P., Aaroe, A., Liang, J., and Puduvalli, V.K. (2023). Tumor microenvironment in glioblastoma: Current and emerging concepts. Neuro Oncol. Adv., 5.","DOI":"10.1093\/noajnl\/vdad009"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1158\/1078-0432.CCR-23-0493","article-title":"Functional Contribution and Clinical Implication of Cancer-Associated Fibroblasts in Glioblastoma","volume":"30","author":"Galbo","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1002\/1878-0261.12569","article-title":"Single-cell RNA-seq reveals the invasive trajectory and molecular cascades underlying glioblastoma progression","volume":"13","author":"Pang","year":"2019","journal-title":"Mol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12935-023-02854-5","article-title":"Tumor microenvironment in ovarian cancer peritoneal metastasis","volume":"23","author":"Mei","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11060-023-04536-8","article-title":"Understanding current experimental models of glioblastoma-brain microenvironment interactions","volume":"166","author":"Yadav","year":"2024","journal-title":"J. Neurooncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Rickard, B.P., Conrad, C., Sorrin, A.J., Ruhi, M.K., Reader, J.C., Huang, S.A., Franco, W., Scarcelli, G., Polacheck, W.J., and Roque, D.M. (2021). Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response. Cancers, 13.","DOI":"10.3390\/cancers13174318"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/neuonc\/noac254","article-title":"Corrigendum to: EGFR, the Lazarus target for precision oncology in glioblastoma","volume":"25","author":"Lin","year":"2023","journal-title":"Neuro Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Barzegar Behrooz, A., Talaie, Z., Jusheghani, F., \u0141os, M.J., Klonisch, T., and Ghavami, S. (2022). Wnt and PI3K\/Akt\/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031353"},{"key":"ref_46","unstructured":"Jackson, G. (2024, November 26). Figure Created Using BioRender. Available online: https:\/\/BioRender.com\/m39f272."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Roane, B.M., Arend, R.C., and Birrer, M.J. (2019). Review: Targeting the Transforming Growth Factor-Beta Pathway in Ovarian Cancer. Cancers, 11.","DOI":"10.3390\/cancers11050668"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Newsted, D., Banerjee, S., Watt, K., Nersesian, S., Truesdell, P., Blazer, L.L., and Craig, A.W. (2018). Blockade of TGF-\u03b2 signaling with novel synthetic antibodies limits immune exclusion and improves chemotherapy response in metastatic ovarian cancer models. Oncoimmunology, 8.","DOI":"10.1080\/2162402X.2018.1539613"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Du, B., and Shim, J.S. (2016). Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer. Molecules, 21.","DOI":"10.3390\/molecules21070965"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/3\/171\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:34:38Z","timestamp":1759919678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/3\/171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["cells14030171"],"URL":"https:\/\/doi.org\/10.3390\/cells14030171","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]}}}